Robin L Jones
Overview
Explore the profile of Robin L Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
361
Citations
6946
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cote G, Chawla S, Demetri G, Kasper B, Jones R, Broto J, et al.
Future Oncol
. 2025 Feb;
:1-9.
PMID: 39932221
Previous phase I/II trials indicate promising activity of lurbinectedin plus doxorubicin (DOX) in leiomyosarcoma (LMS). We describe here the rationale and design of SaLuDo, an open label, randomized, multicenter, seamless...
2.
Wilky B, Schwartz G, Gordon M, El-Khoueiry A, Bullock A, Henick B, et al.
J Clin Oncol
. 2025 Jan;
JCO2402524.
PMID: 39869830
Purpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define...
3.
Pozas J, Thway K, Lindsay D, Fisher C, Smith M, Hayes A, et al.
Eur J Cancer
. 2025 Jan;
217:115229.
PMID: 39809106
Background: Ossifying fibromyxoid tumour is a rare mesenchymal soft tissue sarcoma with uncertain differentiation and variable metastatic potential. Patients And Methods: This study offers a retrospective analysis of 23 patients...
4.
Mavroeidis L, Napolitano A, Huang P, Jones R
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796641
There has been noteworthy progress in molecular characterisation and therapeutics in soft tissue sarcomas. Novel agents have gained regulatory approval by the FDA. Examples are the tyrosine kinase inhibitors avapritinib...
5.
Li K, Gulia A, Duffaud F, Jones R
Oncol Ther
. 2024 Dec;
13(1):1-9.
PMID: 39652252
The systemic treatment landscape for advanced and metastatic chondrosarcoma, a malignancy with limited responsiveness to conventional therapies, has always been notoriously challenging. While standard chemotherapy offers minimal benefits, certain subtypes,...
6.
Johnston E, Winfield J, Arthur A, Blackledge M, Banerjee U, Basso J, et al.
Acad Radiol
. 2024 Nov;
32(2):1100-1107.
PMID: 39592381
Rationale And Objectives: Intratumoral heterogeneity means single site tumor biopsy might not be representative. Here we develop and optimize an MRI-informed robotic multiregional 'smart' biopsy technique in retroperitoneal and pelvic...
7.
Kalofonou F, Napolitano A, Benson C, Miah A, Zaidi S, Lindsay D, et al.
Rare Tumors
. 2024 Nov;
16:20363613241290788.
PMID: 39512363
We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy,...
8.
Giani C, Salawu A, Ljevar S, Denu R, Napolitano A, Palmerini E, et al.
Am J Surg Pathol
. 2024 Oct;
49(1):27-34.
PMID: 39466087
The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS,...
9.
Stacchiotti S, Martini S, Pasquali S, Frezza A, Beretta A, Percio S, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5122-5137.
PMID: 39283723
Purpose: Epithelioid hemangioendothelioma (EHE), an ultra-rare sarcoma, poses therapeutic challenges because of limited efficacy of conventional chemotherapy in advanced cases, necessitating exploration of new treatment avenues and identification of novel...
10.
George S, Blay J, Chi P, Jones R, Serrano C, Somaiah N, et al.
Future Oncol
. 2024 Sep;
20(27):1973-1982.
PMID: 39229786
Somatic activating mutations drive most gastrointestinal stromal tumors (GISTs). Disease progression eventually develops with first-line imatinib, commonly due to secondary mutations, and different kinase inhibitors have various levels of treatment...